**3. Results**

The cohort included 20 patients. The epidemiological characteristics of the recruited patients are reported in Table 1.


**Table 1.** Features of the study population.

Upon initiation of adalimumab therapy, 90% of patients received in combination mesalazine, 60% of patients took systemic corticosteroids and 20% took an immunosuppressant (azathioprine). Clinical, biochemical and endoscopic activity, before starting adalimumab therapy, is reported in Table 2.


**Table 2.** Activity according to Harvey-Bradshaw index (HBI) score, biochemical activity and endoscopic activity according to simple endoscopic score for Crohn's disease (SES-CD) at baseline.

Abbreviations: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), faecal calprotectin (FC).
